Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Astem-101 is an investigational cell therapy consisting of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) delivered via injection. It is being developed by Shanghai Angsheng Biomedical Technology Co.,LTD for the treatment of Moderate to Severe Erectile Dysfunction (ED) associated with Type 2 Diabetes Mellitus. The therapy is currently in Phase 2 clinical trials, with an optimal dose level selected based on Phase 1 study results.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Astem-101.